NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain
CompletedPhase 2NCT00258622
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Purpose: To evaluate the efficacy, tolerability and safety of NS1209 compared to lidocaine and placebo in patients with peripheral chronic neuropathic pain.
Study details
- Official title
- NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study
- Conditions
- Interventions
- Drug: NS1209
- Drug: Lidocaine
- Sponsor
- Danish Pain Research Center
- Collaborators
- NeuroSearch A/S
- Start date
- 2005-11
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Denmark
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age \>18 years * Neuropathic pain and allodynia after a peripheral nerve injury (VAS \>= 4) Exclusion Criteria: * Patients who cannot cooperate and do no understand Danish * Fertile women * Clinically significant abnormality or disease * Drug and alcohol abuse * Clinically abnormal ECG * Hypersensitivity to any of the treatments * Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics except gabapentin, anticoagulants, Na channel blockers and beta blockers * Patients who have previously been treated in a NS1209 study * Patients treated with an investigational drug
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00258622